| | |
| Comment | 15.420 | Hugh Cleland, CFA | Have some compounds that are expected to boost HDL levels significantly. He usually has trouble with pure biotechs, which this one is. They consume vast amounts of cash. Prefers Neptune (NTB-X). | 2007-12-27 | |
| | |
| DON'T BUY | 16.900 | Hugh Cleland, CFA | Strong management. Have an interesting approach to HDL. Currently pre-clinical, so doesn't know if it works in humans or is safe. | 2007-03-26 | |
| | |
| DON'T BUY | 19.110 | Hugh Cleland, CFA | Treatment of Cardiovascular diseases. They’re on to a new way of looking at HDL treatment. Still pre-clinical. Prefers biotech that is at least in phase 2 trials. Too expensive. | 2007-01-24 | |
Experts that have talked about Resverlogix Corp.
Rss Top Picks Feed